Ambrx’ platform will be used to develop a product that has improved biological properties over the FGF-21.



Ambrx and Merck & Co. are collaborating on the development of a therapeutic protein with properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic disorders.


Both parties will utilize Ambrx’ protein technology, ReCODE™, to develop a chemically modified and optimized drug candidate designed to have improved therapeutic properties over the native FGF-21 protein.


The collaboration includes an upfront and R&D payments from Merck. Additionally, Ambrx will be eligible to receive future milestone fees associated with research, development, and commercialization of a drug candidate along with royalties on net sales. The firm also has the right to exercise an end of Phase II profit sharing option.








This site uses Akismet to reduce spam. Learn how your comment data is processed.